Home/Filings/4/0001209191-17-035159
4//SEC Filing

G1 Therapeutics, Inc. 4

Accession 0001209191-17-035159

CIK 0001560241operating

Filed

May 23, 8:00 PM ET

Accepted

May 24, 8:02 PM ET

Size

7.5 KB

Accession

0001209191-17-035159

Insider Transaction Report

Form 4
Period: 2017-05-22
Strum Jay
Chief Scientific Officer
Transactions
  • Conversion

    Common Stock

    2017-05-22+16,66658,569 total
  • Conversion

    Series 1 Preferred

    2017-05-2250,0000 total
    Common Stock (16,666 underlying)
Footnotes (2)
  • [F1]The Preferred Stock automatically converted into Common Stock upon the closing of the Issuer's initial public offering pursuant to the Issuer's Fifth Restated Certificate of Incorporation, as amended, based on the conversion rate in effect at the time of conversion. The Series 1 Preferred Stock converted to Common Stock on a 1-for-3 basis.
  • [F2]The Series 1 Preferred Stock automatically converted into shares of Common Stock upon consummation of the Issuer's initial public offering and had no expiration date.

Issuer

G1 Therapeutics, Inc.

CIK 0001560241

Entity typeoperating
IncorporatedDE

Related Parties

1
  • filerCIK 0001560241

Filing Metadata

Form type
4
Filed
May 23, 8:00 PM ET
Accepted
May 24, 8:02 PM ET
Size
7.5 KB